Salix Pharmaceuticals, Ltd. and Progenics Pharmaceuticals, Inc. today announced that the Food and Drug Administration has approved Relistor (methylnaltrexone bromide) 12 mg/0.6 mL subcutaneous injection for the treatment of opioid-induced constipation (OIC) in patients taking opioids for chronic non-cancer pain. Relistor subcutaneous injection is currently the only available peripherally acting mu opioid receptor antagonist (PAMORA) that is approved for treating OIC at the cause without interfering with the centrally acting analgesic properties of the opioid.

For more details, go to: http://news.salix.com/press-release/fda-approves-relistor-subcutaneous-injection-treatment-opioid-induced-constipation